The stock of Bristol-Myers Squibb Co. (BMY) has gone up by 0.45% for the week, with a -9.99% drop in the past month and a -17.88% drop in the past quarter. The volatility ratio for the week is 2.04%, and the volatility levels for the past 30 days are 2.33% for BMY. The simple moving average for the last 20 days is -3.05% for BMY stock, with a simple moving average of -20.02% for the last 200 days.

Is It Worth Investing in Bristol-Myers Squibb Co. (NYSE: BMY) Right Now?

Bristol-Myers Squibb Co. (NYSE: BMY) has a price-to-earnings ratio of 12.89x that is above its average ratio. Additionally, the 36-month beta value for BMY is 0.35. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 1 rating it as “overweight,” 16 rating it as “hold,” and 1 rating it as “sell.”

The average price predicted by analysts for BMY is $64.05, which is $13.21 above the current price. The public float for BMY is 2.03B and currently, short sellers hold a 1.15% ratio of that float. The average trading volume of BMY on November 20, 2023 was 12.17M shares.

BMY) stock’s latest price update

Bristol-Myers Squibb Co. (NYSE: BMY) has seen a decline in its stock price by 0.00 in relation to its previous close of 50.84. However, the company has experienced a 0.45% gain in its stock price over the last five trading sessions. Seeking Alpha reported 2023-11-17 that Bristol Myers Squibb is facing short-term pressure on financial results due to generic growth impacting its flagship drug Revlimid. BMY is actively investing in new drugs and companies to strengthen its position in fast-growing markets and create synergies with existing drugs. The company has lowered its revenue guidance for Revlimid in 2023 but expects to be back on a growth trajectory in 2025+ through drug approvals and the Mirati acquisition.

Analysts’ Opinion of BMY

Many brokerage firms have already submitted their reports for BMY stocks, with Cantor Fitzgerald repeating the rating for BMY by listing it as a “Neutral.” The predicted price for BMY in the upcoming period, according to Cantor Fitzgerald is $55 based on the research report published on November 15, 2023 of the current year 2023.

BMY Trading at -8.88% from the 50-Day Moving Average

After a stumble in the market that brought BMY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.57% of loss for the given period.

Volatility was left at 2.33%, however, over the last 30 days, the volatility rate increased by 2.04%, as shares sank -9.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.41% lower at present.

During the last 5 trading sessions, BMY rose by +0.45%, which changed the moving average for the period of 200-days by -30.14% in comparison to the 20-day moving average, which settled at $52.16. In addition, Bristol-Myers Squibb Co. saw -29.34% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at BMY starting from Powell Ann, who sale 17,986 shares at the price of $61.25 back on Aug 24. After this action, Powell Ann now owns 27,868 shares of Bristol-Myers Squibb Co., valued at $1,101,642 using the latest closing price.

Plenge Robert M, the EVP, Chief Research Officer of Bristol-Myers Squibb Co., sale 732 shares at $61.14 during a trade that took place back on Aug 03, which means that Plenge Robert M is holding 6,584 shares at $44,754 based on the most recent closing price.

Stock Fundamentals for BMY

Current profitability levels for the company are sitting at:

The net margin for Bristol-Myers Squibb Co. stands at +13.71. The total capital return value is set at 12.08, while invested capital returns managed to touch 8.80. Equity return is now at value 26.87, with 8.75 for asset returns.

Based on Bristol-Myers Squibb Co. (BMY), the company’s capital structure generated 131.09 points at debt to equity in total, while total debt to capital is 56.73. Total debt to assets is 42.05, with long-term debt to equity ratio resting at 116.92. Finally, the long-term debt to capital ratio is 50.60.

When we switch over and look at the enterprise to sales, we see a ratio of 3.00, with the company’s debt to enterprise value settled at 0.22. The receivables turnover for the company is 3.49 and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.25.


In conclusion, Bristol-Myers Squibb Co. (BMY) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.